| Post date: 2021/06/3 |
Mesenchymal stem cells have been proposed as a novel, minimally invasive, well-tolerated, and alternative option in the treatment of Crohn’s fistula. In this regard, in a clinical trial that had been done in Iran, researchers showed MSCs improve refractory perianal fistula in Crohn's disease.
Perianal fistulas in Crohn’s disease are one of the main challenges in inflammatory bowel diseases (IBDs). Some of the fistulas are refractory to any therapeutic strategy. The aim of this study was to evaluate the therapeutic effect of MSCs as a novel promising modality for the treatment of fistulizing Crohn's disease.
This case series clinical interventional study was conducted from 2014 to 2017 at Shariati hospital, an IBD referral center in Tehran, Iran. In total, 5 patients (2 males and 3 females) enrolled in this study. There were no observed adverse events during the six-month follow-up. Both the Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI) scores decreased in all patients after the cell injection.
Read more
Perianal fistulas in Crohn’s disease are one of the main challenges in inflammatory bowel diseases (IBDs). Some of the fistulas are refractory to any therapeutic strategy. The aim of this study was to evaluate the therapeutic effect of MSCs as a novel promising modality for the treatment of fistulizing Crohn's disease.
This case series clinical interventional study was conducted from 2014 to 2017 at Shariati hospital, an IBD referral center in Tehran, Iran. In total, 5 patients (2 males and 3 females) enrolled in this study. There were no observed adverse events during the six-month follow-up. Both the Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI) scores decreased in all patients after the cell injection.
Read more
View: 2121 Time(s) |
Print: 410 Time(s) |
Email: 0 Time(s) |
0 Comment(s)
